Abstract
Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.
| Original language | English (US) |
|---|---|
| Article number | e1311827 |
| Journal | Molecular and Cellular Oncology |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 4 2017 |
| Externally published | Yes |
Keywords
- ATX
- chemoprevention
- cirrhosis
- fibrosis
- HCC
- hepatocellular carcinoma
- LPA
- LPAR1
- NASH
- non-alcoholic steatohepatitis
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research
Fingerprint Dive into the research topics of 'The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer'. Together they form a unique fingerprint.
Cite this
Erstad, D. J., Tager, A. M., Hoshida, Y., & Fuchs, B. C. (2017). The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Molecular and Cellular Oncology, 4(3), [e1311827]. https://doi.org/10.1080/23723556.2017.1311827